WO1990002119A1 - Derives de 1,2,3,4-tetrahydro-isoquinoline - Google Patents
Derives de 1,2,3,4-tetrahydro-isoquinoline Download PDFInfo
- Publication number
- WO1990002119A1 WO1990002119A1 PCT/JP1989/000825 JP8900825W WO9002119A1 WO 1990002119 A1 WO1990002119 A1 WO 1990002119A1 JP 8900825 W JP8900825 W JP 8900825W WO 9002119 A1 WO9002119 A1 WO 9002119A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- phenyl
- substituted
- compound
- methyl
- Prior art date
Links
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical class C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 title claims abstract description 15
- -1 dibenzyloxyphosphinoyl group Chemical group 0.000 claims abstract description 255
- 125000003118 aryl group Chemical group 0.000 claims abstract description 82
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 50
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 41
- 125000005843 halogen group Chemical group 0.000 claims abstract description 33
- 125000003277 amino group Chemical group 0.000 claims abstract description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 27
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 23
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 20
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 19
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract description 17
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims abstract description 15
- 125000004104 aryloxy group Chemical group 0.000 claims abstract description 12
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims abstract description 11
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims abstract description 9
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims abstract description 8
- 125000005110 aryl thio group Chemical group 0.000 claims abstract description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 46
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 21
- 239000002246 antineoplastic agent Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 13
- 229940041181 antineoplastic drug Drugs 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 3
- 125000005418 aryl aryl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 150000003017 phosphorus Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 158
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 58
- 239000003921 oil Substances 0.000 description 51
- 235000019198 oils Nutrition 0.000 description 51
- 229940125904 compound 1 Drugs 0.000 description 37
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 31
- 239000012230 colorless oil Substances 0.000 description 30
- 239000002904 solvent Substances 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 150000002989 phenols Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 5
- OMSCMJGUCKTCEA-UHFFFAOYSA-N 4-chlorobutylsulfanylbenzene Chemical compound ClCCCCSC1=CC=CC=C1 OMSCMJGUCKTCEA-UHFFFAOYSA-N 0.000 description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- KYXSVGVQGFPNRQ-UHFFFAOYSA-N 2-methyl-3,4-dihydro-1h-isoquinoline Chemical compound C1=CC=C2CN(C)CCC2=C1 KYXSVGVQGFPNRQ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 4
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000000101 thioether group Chemical group 0.000 description 4
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 3
- VGISFWWEOGVMED-UHFFFAOYSA-N 1-(chloromethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CCl)=C1 VGISFWWEOGVMED-UHFFFAOYSA-N 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- SUAATVSKKHVVJP-UHFFFAOYSA-N 3-chloropropylphosphonic acid Chemical compound OP(O)(=O)CCCCl SUAATVSKKHVVJP-UHFFFAOYSA-N 0.000 description 3
- WWHJLVMBXXXUFO-UHFFFAOYSA-N 4-(chloromethyl)-1,2-dimethoxybenzene Chemical compound COC1=CC=C(CCl)C=C1OC WWHJLVMBXXXUFO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- ZIXWTPREILQLAC-UHFFFAOYSA-N isoquinolin-8-ol Chemical compound C1=NC=C2C(O)=CC=CC2=C1 ZIXWTPREILQLAC-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036457 multidrug resistance Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000012434 nucleophilic reagent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 229960001722 verapamil Drugs 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- LJQNMDZRCXJETK-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine;hydron;chloride Chemical compound Cl.CN(C)CCCCl LJQNMDZRCXJETK-UHFFFAOYSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960004643 cupric oxide Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 238000006264 debenzylation reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000007154 intracellular accumulation Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- RQKYHDHLEMEVDR-UHFFFAOYSA-N oxo-bis(phenylmethoxy)phosphanium Chemical compound C=1C=CC=CC=1CO[P+](=O)OCC1=CC=CC=C1 RQKYHDHLEMEVDR-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PTDVPWWJRCOIIO-UHFFFAOYSA-N (4-methoxyphenyl)methanethiol Chemical compound COC1=CC=C(CS)C=C1 PTDVPWWJRCOIIO-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XXILDBMRKXAIDA-UHFFFAOYSA-N 1-(3-bromoprop-1-enyl)-4-methoxybenzene Chemical compound COC1=CC=C(C=CCBr)C=C1 XXILDBMRKXAIDA-UHFFFAOYSA-N 0.000 description 1
- UNDGKAXUZXFVJV-UHFFFAOYSA-N 1-(3-chloropropylsulfinyl)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(S(=O)CCCCl)C=C1 UNDGKAXUZXFVJV-UHFFFAOYSA-N 0.000 description 1
- PFZKQAIACYPLAA-UHFFFAOYSA-N 1-(3-chloropropylsulfonyl)-4-methoxybenzene Chemical compound COC1=CC=C(S(=O)(=O)CCCCl)C=C1 PFZKQAIACYPLAA-UHFFFAOYSA-N 0.000 description 1
- MJRVJLUCLPUZER-UHFFFAOYSA-N 1-(chloromethyl)-2,3-dimethoxybenzene Chemical compound COC1=CC=CC(CCl)=C1OC MJRVJLUCLPUZER-UHFFFAOYSA-N 0.000 description 1
- CCAWDIFJOBKBSE-UHFFFAOYSA-N 1-(chloromethyl)-3,5-dimethoxybenzene Chemical compound COC1=CC(CCl)=CC(OC)=C1 CCAWDIFJOBKBSE-UHFFFAOYSA-N 0.000 description 1
- LZBOHNCMCCSTJX-UHFFFAOYSA-N 1-(chloromethyl)-3-methylbenzene Chemical compound CC1=CC=CC(CCl)=C1 LZBOHNCMCCSTJX-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- KXSPCYIITJODSL-UHFFFAOYSA-N 1-[3-(chloromethyl)phenyl]-n,n-dimethylmethanamine;hydrochloride Chemical compound Cl.CN(C)CC1=CC=CC(CCl)=C1 KXSPCYIITJODSL-UHFFFAOYSA-N 0.000 description 1
- JEOITUQBDPRYRG-UHFFFAOYSA-N 1-benzyl-3-chlorobenzene Chemical compound ClC1=CC=CC(CC=2C=CC=CC=2)=C1 JEOITUQBDPRYRG-UHFFFAOYSA-N 0.000 description 1
- HTDQSWDEWGSAMN-UHFFFAOYSA-N 1-bromo-2-methoxybenzene Chemical compound COC1=CC=CC=C1Br HTDQSWDEWGSAMN-UHFFFAOYSA-N 0.000 description 1
- ORPVVAKYSXQCJI-UHFFFAOYSA-N 1-bromo-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1Br ORPVVAKYSXQCJI-UHFFFAOYSA-N 0.000 description 1
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
- ZDFBKZUDCQQKAC-UHFFFAOYSA-N 1-bromo-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1 ZDFBKZUDCQQKAC-UHFFFAOYSA-N 0.000 description 1
- JKXQKGNGJVZKFA-UHFFFAOYSA-N 1-chloro-3-methylbut-2-ene Chemical compound CC(C)=CCCl JKXQKGNGJVZKFA-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- WORNMIRYYMSPOY-UHFFFAOYSA-N 2-(chloromethyl)-1,3-dimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1CCl WORNMIRYYMSPOY-UHFFFAOYSA-N 0.000 description 1
- NJBICLSFUUJIDH-UHFFFAOYSA-N 2-(chloromethyl)-1,4-dimethoxybenzene Chemical compound COC1=CC=C(OC)C(CCl)=C1 NJBICLSFUUJIDH-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- VQUYNUJARXBNPK-UHFFFAOYSA-N 2-chloroethoxybenzene Chemical compound ClCCOC1=CC=CC=C1 VQUYNUJARXBNPK-UHFFFAOYSA-N 0.000 description 1
- UPIMXDQREQJWMR-UHFFFAOYSA-N 2-chloroethoxymethylbenzene Chemical compound ClCCOCC1=CC=CC=C1 UPIMXDQREQJWMR-UHFFFAOYSA-N 0.000 description 1
- UQSMMTFBNJUPGW-UHFFFAOYSA-N 2-chloroethylsulfanylmethylbenzene Chemical compound ClCCSCC1=CC=CC=C1 UQSMMTFBNJUPGW-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- VTWDKFNVVLAELH-UHFFFAOYSA-N 2-methylcyclohexa-2,5-diene-1,4-dione Chemical compound CC1=CC(=O)C=CC1=O VTWDKFNVVLAELH-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 1
- DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- JKXCPAVECBFBOC-UHFFFAOYSA-N 4-chlorobutoxybenzene Chemical compound ClCCCCOC1=CC=CC=C1 JKXCPAVECBFBOC-UHFFFAOYSA-N 0.000 description 1
- JPOGLPLBZWTLJS-UHFFFAOYSA-N 4-chlorobutylsulfinylbenzene Chemical compound ClCCCCS(=O)C1=CC=CC=C1 JPOGLPLBZWTLJS-UHFFFAOYSA-N 0.000 description 1
- NIFAOMSJMGEFTQ-UHFFFAOYSA-N 4-methoxybenzenethiol Chemical compound COC1=CC=C(S)C=C1 NIFAOMSJMGEFTQ-UHFFFAOYSA-N 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- AXBVSRMHOPMXBA-UHFFFAOYSA-N 4-nitrothiophenol Chemical compound [O-][N+](=O)C1=CC=C(S)C=C1 AXBVSRMHOPMXBA-UHFFFAOYSA-N 0.000 description 1
- XXRUQNNAKXZSOS-UHFFFAOYSA-N 5-(chloromethyl)-1,2,3-trimethoxybenzene Chemical compound COC1=CC(CCl)=CC(OC)=C1OC XXRUQNNAKXZSOS-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100129007 Arabidopsis thaliana LTD gene Proteins 0.000 description 1
- 241000616862 Belliella Species 0.000 description 1
- 238000006407 Bischler-Napieralski reaction Methods 0.000 description 1
- ZYUZLEUJKZZXNN-UHFFFAOYSA-N C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 Chemical group C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 ZYUZLEUJKZZXNN-UHFFFAOYSA-N 0.000 description 1
- OIMRYENITBFSJR-UHFFFAOYSA-N COC1=C(C=C2CCN(C(C2=C1OC)CC1=CC=C(C=C1)OC)C)O Chemical compound COC1=C(C=C2CCN(C(C2=C1OC)CC1=CC=C(C=C1)OC)C)O OIMRYENITBFSJR-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- LTEQMZWBSYACLV-UHFFFAOYSA-N Hexylbenzene Chemical compound CCCCCCC1=CC=CC=C1 LTEQMZWBSYACLV-UHFFFAOYSA-N 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101100505385 Mus musculus Gpd1 gene Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JETFNRIIPBNRAT-UHFFFAOYSA-N butylsulfanylbenzene Chemical compound CCCCSC1=CC=CC=C1 JETFNRIIPBNRAT-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical group [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229940116318 copper carbonate Drugs 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 229940112669 cuprous oxide Drugs 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000006704 dehydrohalogenation reaction Methods 0.000 description 1
- VLCINIKIVYNLPT-UHFFFAOYSA-J dicalcium;hydrogen phosphate Chemical compound [Ca+2].[Ca+2].OP(O)([O-])=O.[O-]P([O-])([O-])=O VLCINIKIVYNLPT-UHFFFAOYSA-J 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- SWGQITQOBPXVRC-UHFFFAOYSA-N methyl 2-bromobenzoate Chemical compound COC(=O)C1=CC=CC=C1Br SWGQITQOBPXVRC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005146 naphthylsulfonyl group Chemical group C1(=CC=CC2=CC=CC=C12)S(=O)(=O)* 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- GMMWKYSAFBYKHU-UHFFFAOYSA-N octylsulfanylbenzene Chemical compound CCCCCCCCSC1=CC=CC=C1 GMMWKYSAFBYKHU-UHFFFAOYSA-N 0.000 description 1
- JPMVDVIGHJCZJW-UHFFFAOYSA-N octylsulfonylbenzene Chemical compound CCCCCCCCS(=O)(=O)C1=CC=CC=C1 JPMVDVIGHJCZJW-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- DLRJIFUOBPOJNS-UHFFFAOYSA-N phenetole Chemical compound CCOC1=CC=CC=C1 DLRJIFUOBPOJNS-UHFFFAOYSA-N 0.000 description 1
- FQDHUNHDBJDGFR-UHFFFAOYSA-N phenylmethanethiol Chemical compound SCC1=CC=CC=C1.SCC1=CC=CC=C1 FQDHUNHDBJDGFR-UHFFFAOYSA-N 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N phenylmethylmercaptan Natural products SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 101150108030 ppiD gene Proteins 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical group CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
Definitions
- the present invention relates to a novel 1,2,3,4-tetrahydroisoquinoline derivative having an effect of enhancing the antitumor effect of an anticancer agent on various cancer cells including multidrug-resistant cancer cells and useful for treating cancer It is about.
- the present inventors have conducted intensive studies on compounds that enhance the antitumor effect of anticancer drugs against various cancer cells including multidrug-resistant cancer cells. As a result, the compounds represented by the following general formula [I] showed excellent antitumor effects. (4) The present invention has been completed by discovering that it exhibits strong action.
- the present invention has the general formula
- R 2 represents a lower alkyl group or a methylene group together with R 1 or R 3
- R 1 and R 3 each represent a lower alkyl group or a group together with R 2
- the aryl lower alkyl group is a group in which a hydrogen atom on an aromatic ring is a lower alkyl group, a lower alkyloxy group, an N-benzyl-N-methylamino group, a halogen atom, an amino group, an N, N-di-lower alkylamino Group, (N, N-di-lower alkylamino) methyl group, (N-benzyl-N-methylamino) methyl group, morpholinomethyl group, nitro group, It may be substituted with the same or different 1 to 3 substituents selected from the group consisting of a tylenedioxy group and a lower alkyloxycarbonyl group.
- an unsubstituted benzyl group is excluded, and an aryl group (where the hydrogen atom on the aromatic ring is a halogen atom, lower alkyloxy group, nitro group, amino group, ⁇ , ⁇ -di-lower) It may be substituted with an alkylamino group or a lower alkyloxycarbonyl group, provided that an unsubstituted phenyl group is excluded, or a compound represented by the formula:-(CHjm-A (where A is a halogen atom, a lower alkylthio group) Group, lower alkylsulfinyl group, lower arylsulfonyl group, aryl lower alkylthio group, aryl lower alkyl sulfinyl group, aryl lower alkylsulfonyl group, arylaryl, arylsulfinyl group, arylsulfonyl group, arylyl A lower alkyloxy
- R 4 represents a lower alkyl group
- a i represents a phenyl group which may be substituted by 1 to 3 lower alkyloxy groups
- II represents 0 to 2].
- 4-tetrahydroisoquinoline derivatives or It is intended to provide a pharmaceutically acceptable acid addition salt thereof and a use thereof as an agent for enhancing the antitumor effect of the anticancer agent.
- a lower alkyl group means a straight-chain or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl. -Butyl, tert-butyl, pentyl, hexyl, etc.
- the lower alkenyl group means a linear or branched alkenyl group having 1 to 6 carbon atoms, for example, a vinyl group, an aryl group, an isopropyl group, a 2-butenyl group, a 3-butenyl group, a 2-butenyl group.
- An aryl lower alkenyl group refers to a lower alkenyl group in which a hydrogen atom on an aromatic ring is substituted with an aromatic hydrocarbon group which may be substituted with a lower alkyloxy group, for example, a styryl group, a cinnamyl group, or a 4-phenyl- 3-butenyl group, 5-phenyl-4-pentenyl group, 3- (1-naphthyl) -2-propenyl group, 2-methoxycinnamyl group, 3-methoxycinnamyl group, 4-methoxycinnamyl group, 4-ethoxycinnamyl group, 4- (4-methoxyphenyl) -3-butenyl group, etc.
- An aryl lower alkyl group is a group in which a hydrogen atom on an aromatic ring is a lower alkyl group, a lower alkyloxy group, an N-benzyl-N-methylamino group, a halogen atom, an amino group, an N, N-di-lower alkylamino group, (N , N-di-lower alkylamino) methyl group, (N-benzyl-N-methylamino) tyl group, morpholinomethyl group, nitro group, methylenedioxy group and lower alkyloxycarponyl group
- a lower alkyl group (excluding an unsubstituted benzyl group) substituted with an aromatic hydrocarbon group which may be substituted with the same or different 1 to 3 substituents, for example, 1- Phenylethyl group, 2-phenylethyl group, 3-phenylpropyl group, 4-phenylbutyl group, 5-phenylpentyl group
- An aryl group is an aromatic group in which a hydrogen atom on an aromatic ring may be substituted with a halogen atom, a lower alkyloxy group, a nitro group, an amino group, an N, N-di-lower alkylamino group or a lower alkyloxycarbonyl group. It means a hydrocarbon group (excluding an unsubstituted phenyl group), for example, 2-chlorophenyl group, 3-chlorophenyl group, 4-chlorophenyl group, 2-methoxyphenyl group.
- a lower alkyloxy group is a straight-chain or branched alkyl having 1 to 6 carbon atoms. It means a methoxy group, for example, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group.
- the halogen atom means a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
- the N, N-di-lower alkylamino group means an amino group substituted with two same or different lower alkyl groups, such as N, N-dimethylamino group, N-ethyl-N-methylamino group, , N-ethylamino group, N-ethyl-N-propylamino group, N, N-dipropylamino group, ⁇ , ⁇ -dibutylamino group and the like.
- ⁇ , ⁇ -di-lower alkylaminomethyl group means a methyl group substituted by ⁇ , ⁇ -di-lower alkylamino group as defined above, for example, ⁇ , ⁇ -dimethylaminomethyl group, ⁇ - Examples thereof include ethyl- ⁇ -methylaminomethyl group, ⁇ , ⁇ -ethylaminomethyl group, ⁇ , ⁇ -dipropylaminomethyl group, ⁇ , ⁇ -dibutylaminomethyl group and the like.
- the lower alkyloxycarbonyl group means an alkyloxycarbonyl group having 2 to 7 carbon atoms, such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl and the like.
- the lower alkylthio group means a linear or branched alkylthio group having 1 to 6 carbon atoms, and examples thereof include a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, and a butylthio group.
- the lower alkylsulfinyl group means a linear or branched alkylsulfinyl group having 1 to 6 carbon atoms, such as a methylsulfinyl group, an ethylsulfinyl group, a propylsulfinyl group, an isopropylsulfinyl group, And a tylsulfinyl group.
- the lower alkylsulfonyl group means a linear or branched alkylsulfonyl group having 1 to 6 carbon atoms, for example, mesyl group, ethylsulfonyl group, propylsulfonyl group, isopropylsulfonyl group, butylsulfonyl group. Groups and the like.
- An aryl lower alkylthio group is an aromatic hydrocarbon group in which a hydrogen atom on an aromatic ring may be substituted with a halogen atom, a lower alkyloxy group, a nitro group, an amino group, or an N, N-di-lower alkylamino group.
- a substituted lower alkylthio group means, for example, benzylthio, 2-phenylethylthio, 3-phenylpropylthio, 4-phenylbutylthio, 4-chlorobenzylthio, 2-methoxybenzylthio, etc. And 3-methoxybenzylthio, 4-methoxybenzylthio, 4-nitrobenzylthio, 4-aminobenzylthio, 4- (N, N-dimethylamino) benzylthio and the like.
- An aryl lower alkylsulfinyl group is an aromatic carbon atom in which a hydrogen atom on an aromatic ring may be substituted with a halogen atom, a lower alkyloxy group, a nitro group, an amino group or an N, N-di-lower alkylamino group.
- a lower alkylsulfinyl group substituted with a hydrogen group such as benzylsulfinyl group, 2-phenylethylsulfinyl group, 3-phenylpropylsulfinyl group, 4-phenylbutylsulfinyl group, Benzylsulfinyl, 4-methoxybenzylsulfinyl, 4-nitrobenzylsulfinyl, 4-aminobenzylsulfinyl, 4- (N, N-dimethylamino) benzylsulfinyl, etc. It is.
- An aryl lower alkylsulfonyl group is a hydrogen atom on an aromatic ring which is Lower alkylsulfonyl group substituted by an aromatic hydrocarbon group which may be substituted by a substituent, a lower alkyloxy group, a nitro group, an amino group or an N, N-di-lower alkylamino group.
- An arylthio group refers to a phenyl or naphthylthio group in which a hydrogen atom on an aromatic ring may be substituted with a halogen atom, a lower alkyloxy group, a nitro group, an amino group or an N, N-di-lower alkylamino group.
- a phenylthio group refers to a phenyl or naphthylthio group in which a hydrogen atom on an aromatic ring may be substituted with a halogen atom, a lower alkyloxy group, a nitro group, an amino group or an N, N-di-lower alkylamino group.
- 2-nitrophenylthio group, 3-nitrophenylthio group, 4-nitrophenylthio group, 4-aminophenylthio group, 4- (N, N-dimethylamino) phenylthio group and the like can be used.
- Arylsulfinyl group is phenyl or naphthyls in which a hydrogen atom on the aromatic ring may be replaced by a halogen atom, lower alkyloxy group, nitro group, amino group, N, N-di-lower alkylamino group Luffinyl group, such as enylsulfinyl, 1-naphthylsulfinyl, 2-naphthylsulfi
- An arylsulfonyl group refers to a phenyl or naphthylsulfonyl group in which a hydrogen atom on an aromatic ring may be substituted with a halogen atom, lower alkyloxy group, nitro group, amino group, N, N-di-lower alkylamino group.
- phenylsulfonyl 1-naphthylsulfonyl, 2-naphthylsulfonyl, 4-chlorophenylsulfonyl, 4-methoxyphenylsulfonyl, 4-nitrophenylsulfonyl, 4- Aminophenylsulfonyl group, 4- (N, N-dimethylamino) phenylsulfonyl group and the like can be used.
- An aryl lower alkyloxy group is an aromatic hydrocarbon in which a hydrogen atom on an aromatic ring may be substituted with a halogen atom, a lower alkyloxy group, a nitro group, an amino group, an N, N-di-lower alkylamino group.
- a lower alkyloxy group substituted with a group such as benzyloxy, 2-phenylethoxy, 3-phenylpropoxy, 4-chlorobenzyloxy, 2-methoxybenzyloxy, 3 -Methoxybenzyloxy, 4-methoxybenzyloxy, 3-nitrobenzyloxy, 4-nitrobenzyloxy, 4-aminobenzyloxy, 4- (N, N-dimethylamino) benzyloxy, etc. Is mentioned.
- An aryloxy group means a phenoxy or naphthoxy group in which a hydrogen atom on the aromatic ring may be represented by a halogen atom, a lower alkyloxy group, a nitro group, an amino group, an N, N-di-lower alkylamino group.
- a hydrogen atom on the aromatic ring may be represented by a halogen atom, a lower alkyloxy group, a nitro group, an amino group, an N, N-di-lower alkylamino group.
- phenoxy, 1-naphthoxy, 2-naphthoxy, 4-chlorophenoxy, 4-methoxyphenoxy, 4-nitrophenoxy, 4-aminophenoxy, 4- (N, N-dimethylamino) phenoxy Motoki is fisted.
- N-benzyl-N-lower alkylamino group means an amiso group which is S-substituted with a benzyl group or a lower alkyl group, such as an N-benzyl-N-methylamino group, -Benzyl-N-ethylamino group, N-benzyl-N-propylamino group and the like.
- N-phenyl-N-lower alkylamino group means an amino group substituted with a phenyl group and a lower alkyl group, for example, N-methyl-N-phenylamino, N-ethyl-N-phenylamino, N- A phenyl-N-propylamino group, an N-butyl-N-phenylamino group and the like.
- di-lower alkyloxyphosphinoyl group means a dialkyloxyphosphinoyl group having two identical lower alkyloxy groups, such as dimethoxyphosphinoyl group and diethoxyphosphinoyl group. And dipropoxyphosphinoyl groups, dibutoxyphosphinoyl groups and the like.
- the leaving group that can be substituted with an aryloxy group includes a halogen atom such as a chlorine atom, a bromine atom or an iodine atom, an alkylsulfonyloxy group such as a methanesulfonyloxy group, or a phenylsulfoninoleoxy group, P -Arylsulfonyloxy groups such as trisulfonyloxy groups.
- Hue optionally substituted with 1 to 3 lower alkyloxy groups examples include a 2-methoxyphenyl group, a 3-methoxyphenyl group, a 4-methoxyphenyl group, a 3,4-dimethoxyphenyl group, a 3,4,5-trimethoxyphenyl group, 4-ethoxyphenyl group, 4_propoxyphenyl group, 4-isopropoxyphenyl group and the like.
- the method for producing the compound according to the present invention is described below.
- the compound of the present invention [1] has the general formula
- R 21 represents the combined such connexion methylene group or with R 11 or R 31 or a lower alkyl group
- R 11 and R 31 indicate carded is either a lower alkyl group
- R 4 represents a lower alkyl group
- Ar represents a phenyl group which may be substituted by 1 to 3 lower alkyloxy groups
- R 5 described below is an aryl group, a base and metallic copper or a monovalent or divalent copper salt
- R 5 is a lower alkenyl group, an aryl lower alkenyl group (the aryl lower alkenyl group may have a hydrogen atom on the aromatic ring substituted by a lower alkyloxy group), an aryl lower alkyl group (the aryl lower alkyl group)
- the hydrogen atom on the aromatic ring is a lower alkyl group, lower alkyloxy group, N-benzyl-N-methylamino group, halogen atom, amino group, N, N-di-lower alkylamino group, (N, N-di- 1 to 3 identical or different substituents selected from the group consisting of lower alkylamino) methyl, (N-benzylmethylamino) methyl, morpholinomethyl, nitro, methylenedioxy and lower alkyloxycarbonyl (Except for unsubstituted benzyl groups), aryl groups (where the hydrogen atom on the aromatic ring is halogen) Child, a
- an unsubstituted phenyl group is excluded, or a compound represented by the formula: (CH 2 ) mA (where A is a halogen atom, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, an aryl lower alkylthio group)
- A is a halogen atom, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, an arylthio group
- an arylsulfinyl group, an arylsulfonyl group, an arylthio group, an arylsulfinyl group, an arylsulfonyl group, an aryl lower alkyloxy group or an aryloxy group the aryl lower alkylthio group
- Lower alkyloxy group, nitro group, amino group May be substituted with an N, N-di-lower alkylamino group), N-benzyl-N-lower alkylamino group, N-phenyl-N-lower alkylamino group, N, N- X represents a di-lower alkylamino group, di-lower alkyloxyphosphinoyl group or dibenzyloxyphosphinoyl group, and m represents 2 to 4); in general, it can be prepared by reacting a compound represented by] a leaving group substitutable by Ariruokishi group, and a group R 5 which is introduced into the new on isoquinoline ring elimination or substitution If it has a possible halogen atom, it may be dehydrohalogenated by treatment with a base, if desired, or a thiol compound, hydroxyl compound, secondary amine, trialkyl phosphite, dialkyl phosphite, dibenzyl
- the compound of the present invention represented by the above general formula [I] includes a phenolic compound represented by the general formula [ ⁇ ] and a phenolic compound represented by the general formula [ ⁇ ] except for a compound in which R 1 or R 3 is an aryl group.
- the compound can be produced by subjecting a compound represented by the formula [ ⁇ ] (excluding a compound in which R 5 is an aryl group) to a condensation reaction in the presence of a base.
- the condensation reaction is preferably performed using a suitable solvent, and examples of the solvent include acetone, acetonitrile, methanol, benzene, dioxane, tetrahydrofuran, dimethyl sulfoxide, dimethylformamide and the like.
- Examples of the base used in the reaction include inorganic bases such as alkali metal carbonates, alkali metal hydrogencarbonates, alkali metal hydroxides, alkali metal hydrides, and alkali metal alkoxides.
- the reaction is carried out by dissolving compound [ ⁇ ] in the above solvent, adding an appropriate base, and further adding compound [ ⁇ ] at 0 ° C to the boiling point of the solvent, preferably at room temperature to 6 CTC for 30 minutes to 24 hours. It can be performed by reacting.
- the amount of the compound [ ⁇ used is from 1 to L0 mol, preferably from 1 to L.2 mol, per 1 mol of the compound [ ⁇ ].
- the amount of the inorganic base to be used is 1 to 10 mol, preferably 1 to 2.4 mol, per 1 mol of compound [ ⁇ ].
- a phenolic compound [ ⁇ ] and a compound [ ⁇ ] can be produced by performing a so-called Ullnmnn reaction in a suitable solvent in the presence of a copper catalyst and a base.
- a suitable solvent eg, pyridine, collidine, quinoline, 90/02119 16 Dissolve compound [ ⁇ ] in tilformamide, dimethylacetamide, dimethylsulfoxide, hexamethylphosphoric triamide, diglyme, etc.
- a suitable inorganic base eg, alkali metal carbonate, alkali hydroxide
- a suitable copper catalyst eg, copper powder, cuprous halide, cupric halide, cuprous oxide, cupric oxide, copper carbonate, copper acetate, etc.
- the reaction can be carried out by reacting compound [m] at locrc to the boiling point of the solvent for 1 hour to 3 days.
- the amount of each compound used is 1 to 5 moles, preferably 1 to 2 moles, for each of the inorganic base, the copper catalyst, and the compound [based on the compound [ ⁇ ] ⁇ mol.
- a compound represented by the formula wherein R 1 or R 3 is represented by the formula: 4C3 ⁇ 4X 1 (wherein X 1 represents a halogen atom and m represents 2 to 4) [ ⁇ ] can be converted to a compound in which R 1 or R 3 is a lower alkenyl group such as a vinyl group, an aryl group or a 3-butenyl group through dehydrogenation by treatment with a base. it can.
- the dehydrohalogenation reaction is carried out using a solvent that does not adversely affect the reaction, for example, an alcohol, tetrahydrofuran, dimethylformamide, dimethylsulfoxide, toluene, benzene, or the like, using a suitable base such as alkali metal hydroxide,
- a suitable base such as alkali metal hydroxide
- the reaction is carried out by allowing a base such as an alkali metal alkoxide, triethylamine, 1,8-diazabicyclo [5.4.0] -7-pentadecene to act at 0 to the boiling point of the solvent, preferably at room temperature to 60 ° C for 30 minutes to 10 hours. be able to.
- the amount of the base to be used is 1-10 mol, preferably 1-1.5 mol, per 1 mol of compound [].
- the compound of the present invention [[] having the above halogen atom can be used as a nucleophilic reagent such as a thiol compound, a hydroxyl group compound, a secondary amine, a trialkyl phosphite, a dialkyl phosphite, or a dibenzyl phosphite.
- a nucleophilic reagent such as a thiol compound, a hydroxyl group compound, a secondary amine, a trialkyl phosphite, a dialkyl phosphite, or a dibenzyl phosphite.
- R 1 or R 3 is a group represented by the following formula: ⁇ cH 2 ) i A 1 (where A 1 is a lower alkylthio group, an aryl lower alkylthio group, an arylthio group, an aryl lower alkyloxy group, or an aryloxy group (the aryl lower alkylthio group) , Arylthio, aryl lower alkyloxy and aryloxy groups have hydrogen atoms on the aromatic ring substituted by halogen atoms, lower alkyloxy groups, nitro groups, amino groups or ⁇ , ⁇ -di-lower alkylamino groups.
- a suitable solvent eg, alcohol, dimethylformamide, dimethylsulfoxide, benzene, toluene, tetrahydrofuran or the like
- a thiol compound eg., a hydroxyl compound, a secondary amine, a trialkyl phosphite
- a suitable base eg, alkali metal carbonate, alkali metal hydroxide, alkali metal alkoxide, alkali metal hydride, etc.
- the used amount of the nucleophilic reagent is 1 mole to a large excess with respect to 1 mole of the compound [ ⁇ ], and the used amount of the base is 1 to 1.5 mole.
- the compound [I ′ ′] in which the group represented by R 1 or R 3 has a sulfide group is obtained by converting this group to a sulfinyl group using an oxidizing agent. Or a sulfonyl group.
- a suitable oxidizing agent eg, methax oral perbenzoic acid, hydrogen peroxide
- Water, tetrabutylammonium-oxone, etc. can be added, and the reaction can be carried out at 0 to 60 ° C, preferably at 0 ° C to room temperature for 1 hour to 2 days to oxidize.
- the amount of the oxidizing agent to be used is 1 to 1.2 moles for sulfinylation and 2 to 3 moles for sulfonylation with respect to 1 mole of the compound [] '].
- the compound [ ⁇ ′′] in which the group represented by R 1 or R 3 has a double- ended group is converted to a primary amino group using a reducing agent. This can be reduced to a group, and further reduced to a dimethylamino group by a reductive alkylation reaction.
- tin chloride ( ⁇ ) is added to the nitro compound [ ⁇ ′′] in an appropriate solvent (eg, alcohol, ethyl acetate), and the mixture is allowed to act at 70 ° C. for 30 minutes to 2 hours.
- an appropriate solvent eg, alcohol, ethyl acetate
- the use amount of tin chloride (III) is 3 to 10 mol, preferably: to 5 mol, per 1 mol of the compound [III,].
- a suitable solvent for example, acetonitrile, acetic acid, tetrahydrofuran, etc.
- a suitable reducing agent for example, sodium borohydride, sodium borohydride, formic acid.
- the amino group can be converted to a dimethylamino group by adding the compound at room temperature to the solvent for 2 to 10 hours.
- the amount of formaldehyde used is 2 to 10 moles per mole of primary amino compound, and the amount of reducing agent used is 3 to 10 moles.
- the product obtained in each of the above steps can be purified by a known purification method such as chromatography, recrystallization, solvent extraction, precipitation, or distillation alone or in an appropriate combination. It can be separated and purified.
- the phenolic compound [ ⁇ ] as a raw material is produced according to a known method [for example, see Chemical 'and Pharmaceutical' Brutin ((:) 1601.?1131> 111.8111.), (6), 879 (1967)). That is, the general formula
- Ar represents a phenyl group which may be substituted with 1 to 3 lower alkyloxy groups, ⁇ represents 0 to 2, and X 2 represents a halogen atom, a hydroxyl group, or a lower alkyloxy group.
- R 23 represents a connexion methylol alkylene group with a lower alkyl group, or R 13 or R 33, or R 13 and R 33 represents any one of a lower alkyl group, with P, Z3 A methylene group and the other a benzyl group, and Ar and ⁇ have the above-mentioned meanings].
- the present compound [ ⁇ ] is subjected to ⁇ -alkylation with a lower alkyl halide, and then the imidium salt is reduced with a reducing agent such as sodium borohydride to give a 1,2,3,4-tetrahydro 1 isoquinoline derivative.
- the phenolic compound represented by the general formula [ ⁇ ] is obtained through debenzylation by the action of an acid such as hydrochloric acid or catalytic hydrogenation.
- the compound is reduced with a reducing agent such as sodium borohydride, and the resulting 1,2,3,4-tetrahydroisoquinoline derivative is reacted with an alkyl halide to undergo ⁇ -alkylation.
- the phenolic compound represented by the general formula [ ⁇ ] can be obtained by debenzylation by action or catalytic hydrogenation.
- the raw material compound [ ⁇ ] a commercially available compound can be used. However, if necessary, the hydroxyl group of a commercially available alcohol or an alcohol obtained by a known method can be removed by an ordinary method. It is also possible to use a compound converted to a leaving group [Journal of the American Chemical Society] (J. Am. Chem. Soc.), ⁇ , 2540 (1938)]. Alcohols that can be used as a raw material include, for example, reducing the corresponding carboxylic acids commercially available or produced by a known method with a reducing agent such as aluminum hydride, or reducing the carboxylic acids after converting them into esters. [Journal of Medicine 'Chemistry'-(J. Med.
- dihaloalkanes can be used as they are, or can be converted to various halides by substituting one of the halogen atoms with a nucleophilic reagent in the presence of an appropriate base, and then use them! : Ger. (East) DD202, 690, Chemical 'Chemical Abstracts, 101, 6798S (1984); Jar-Nal' ob 'Organic' Chemistry (J. 0rg. Chem.),
- the sulfide group can be converted to a sulfinyl group or a sulfonyl group with an appropriate oxidizing agent and used. Vol., P. 642 (1963); Journal 'Ob di American' Chemical 'Society (J. Am. Chem. Soc), 111, 258 (1989)] B
- Adriamicin potentiates the antitumor effect of multidrug-resistant cancer cells P388 / ADR, a multidrug-resistant cancer cell that has acquired resistance to anti-cancer drugs such as adriamycin, daunomycin, vincristine, vinblastine, and actinomycin D, for 3 days with 0.5AM of each test drug and a prescribed amount of ADR Cultured. The cell number is then measured and ADR IC 5 . The value (the concentration of ADR that inhibits the growth of cancer cells by 50%) was determined, and the dose modifying factor (hereinafter abbreviated as DMF), which is an index of the antitumor effect enhancing effect, was calculated according to the following formula. The result is first 3 '. One - P388 / ilDi this pair for ADR single IC S.
- DMF dose modifying factor
- ADR IC 6 for drug combination against P388 / ADR Each test drug alone showed almost no growth inhibition in ⁇ . ⁇ ⁇ ⁇ .
- the compound of the present invention increased the sensitivity of multidrug-resistant cancer cells to ADR at 0.5%, and the effect was superior to that of the control drug, verapamil.
- the compound according to the present invention exhibited ADK in multidrug-resistant cancer cells even at a low concentration at which the control drug verapamil had no significant effect, that is, at 0.1 iM. Has the effect of increasing intracellular accumulation of. Table 2
- the compound of the present invention has an excellent antitumor effect enhancing effect on multidrug-resistant cancer cells as compared with known compounds. On the other hand, it is expected to provide more effective treatment.
- a substance having an antitumor effect and a 1,2,3,4-tetrahydroisoquinoline derivative having an antitumor effect enhancing effect on multidrug-resistant cancer cells can be administered separately from each other. It is also possible to mix both in advance and to administer them simultaneously.
- oral preparations such as tablets, capsules, powders, granules or liquids, or solutions or suspensions, for example.
- Sterile liquid parenteral preparations Solid preparations can be produced as they are in the form of tablets, capsules, granules or powders, or they can be produced using appropriate additives.
- additives include sugars such as lactose and glucose, flours such as corn, wheat and rice, fatty acids such as stearic acid, inorganic salts such as magnesium aluminate metasilicate and calcium phosphate calcium phosphate, and the like.
- synthetic polymers such as polyvinylpyrrolidone or polyalkylene glycol, for example, fatty acid salts such as calcium stearate or magnesium stearate, for example, stearyl alcohol or benzyl alcohol Alcohols such as coal, synthetic cellulose derivatives such as methylcellulose, carboxymethylcellulose, ethylcellulose or hydroxypropylmethylcellulose, and other commonly used additives such as water, gelatin, talc, vegetable oil, and arabia gum.
- fatty acid salts such as calcium stearate or magnesium stearate
- stearyl alcohol or benzyl alcohol Alcohols such as coal
- synthetic cellulose derivatives such as methylcellulose, carboxymethylcellulose, ethylcellulose or hydroxypropylmethylcellulose
- other commonly used additives such as water, gelatin, talc, vegetable oil, and arabia gum.
- Solid tablets such as tablets, capsules, granules and powders generally contain from 0.1 to 100% by weight, preferably from 5 to 100% by weight of active ingredient.
- Liquid preparations can be prepared by using appropriate additives usually used in liquid preparations such as water, alcohols or plant-derived oils such as soybean oil, peanut oil or sesame oil, and suspensions, syrups or injections. It is manufactured in the form of an agent or the like.
- Suitable solvents for parenteral intramuscular, intravenous or subcutaneous injection include, for example, distilled water for injection, aqueous lidocaine hydrochloride (for intramuscular injection), physiological saline, and glucose.
- An aqueous solution, ethanol, a liquid for intravenous injection for example, an aqueous solution such as sodium citrate and sodium ⁇ :]
- an electrolyte solution for intravenous drip infusion and intravenous injection
- a mixed solution thereof are included.
- these injections may be in the form of a powder which has been dissolved in advance or a powder to which an appropriate additive has been added, which is dissolved at the time of use.
- These injections usually contain 0.1 to 10% by weight, preferably 1 to 5% by weight, of the active ingredient.
- Liquid preparations such as suspensions or syrups for oral administration contain 0.5 to 10% by weight of active ingredient.
- the dosage of the antitumor effect enhancer of the present invention varies depending on the age, health condition, body weight, or symptoms of the patient, but is 0.1 to 10 mg / kg per day for adults by parenteral administration, or oral.
- the dose is 0.5 to 50 ing / kg for adults per day after administration.
- the title compound is obtained as a colorless oil in the same manner as in Example 1, using Compound 1 and 4-butyl butylsulfonylbenzene. Yield 64%.
- IR (neat, cm 1 ): 2938, 1605, 1515, 1497, 1467, 1419, 1371, 1245, 1176, 1119, 1080,
- Example 1 8- [3- (N-benzyl- ⁇ '-methylaminomethyl) benzyloxy] -6,7-dimethyl
- Example 1 was prepared using 1- (4-methoxybenzyl) -2-methyl-1,2,3,4-tetrahydroisoquinoline compound 1 and N-benzyl-3-culomethylmethylbenzylamine hydrochloride. To give the title compound as a colorless oil. Yield 79
- the title compound is obtained as a pale yellow oil in the same manner as in Example 1 using compound 1 and 3,4-dimethoxybenzyl chloride. Yield 45 ° / 0 .
- IR (neat, cm 1 ): 2932, 1605, 1584, 1515, 1497, 1452, 1245, 1119, 1089, 1038, 801,
- IR (neat ', o3 ⁇ 4): 2944, 1608, 1518, 1464, 1344, 1245, 1179, 1119, 1047, 1008, 852, 750
- IR (chamber t, cm): 2956, 1605, 1584, 1515, 1497, 1344, 1245, 1176, 1122, 1038, 825,
- IR (neat, cm 1 ): 2932, 1611, 1584, 1461, 1344, 1302, 1242, 1179, 1122, 1038, 822,
- IR (CHC1 3, cm 1) 2938, 1611, 1584, 1525, 1458, 1344, 1317, 1236, 1179, 1113, 1062, 858,747
- IRCneat, cm 2938, 1719, 1611, 1503, 1463, 1344, 1230, 1161, 1104, 1071, 846, 762
- Example 105 90% ethanol 3 ⁇ was added to the compound lg of Example 67, and distilled water for injection containing 12 in J2 of propylene glycol, 2 g of citric acid and 0.3 g of sodium citrate was added thereto, and the total amount of the injection was 600 ID £.
- Example 105 90% ethanol 3 ⁇ was added to the compound lg of Example 67, and distilled water for injection containing 12 in J2 of propylene glycol, 2 g of citric acid and 0.3 g of sodium citrate was added thereto, and the total amount of the injection was 600 ID £.
- Example 105 90% ethanol 3 ⁇ was added to the compound lg of Example 67, and distilled water for injection containing 12 in J2 of propylene glycol, 2 g of citric acid and 0.3 g of sodium citrate was added thereto, and the total amount of the injection was 600 ID £.
- Example 105 90% ethanol 3 ⁇ was added to the compound lg of Example 67, and distilled water
- Example 67 The ingredients of Example 67 were mixed in a ratio of 100 g of the compound of Example 67, lactose 200 g, Avicel 50 g, corn starch 46 g and magnesium stearate 4 g, and compression-molded according to a conventional method. Make tablets. Industrial applications
- the 1,2,3,4-tetrahydroisoquinoline derivative of the present invention has a stronger antitumor effect on various types of cancer cells, including multidrug-resistant cancer cells, than known compounds. It is expected to be very useful in '
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Dérivés de 1,2,3,4-tétrahydro-isoquinoline représentés par la formule (I) et agents de potentialisation de l'effet antitumoral contenant ces composés en tant qu'ingrédients actifs. Dans la formule, R2 représente un groupe alkyle inférieur ou, lorsqu'il est combiné avec R1 ou R3, il représente un groupe méthylène, un élément parmi R1 ou R3 représente un groupe alkyle inférieur ou, lorsqu'il est combiné avec R2, il représente un groupe méthylène, et l'autre représente un groupe alcényle inférieur, un groupe alcényle inférieur-aryle substitué ou non substitué, un groupe alkyle inférieur-aryle substitué ou non substitué (à condition que l'on omette un groupe phényle non substitué), un groupe aryle substitué ou non substitué (à condition que l'on omette un groupe phényle non substitué), ou un groupe représenté par -(CH¿2?)m-A (où A représente un atome d'halogène, un groupe alkylsulfonyle inférieur, un groupe alkylthio inférieur-aryle substitué ou non substitué, un groupe alkylsulfinyle inférieur-aryle substitué ou non substitué, un groupe alkylsulfonyle inférieur-aryle substitué ou non substitué, un groupe arylthio substitué ou non substitué, un groupe arylsulfinyle substitué ou non substitué, un groupe arylsulfonyle substitué ou non substitué, un groupe alkyloxy substitué ou non substitué ou un groupe aryloxy substitué ou non substitué, un groupe N-benzyle-N(alkyle inférieur)amino, un groupe N,N-di(alkyle inférieur)amino, un groupe di(alkyloxy inférieur)phosphinoyle ou un groupe dibenzyloxyphosphinoyle, et m représente 2 ou 4), R?4¿ représente un groupe alkyle inférieur, Ar représente un groupe phényle éventuellement substitué par 1 à 3 groupes alkyloxy inférieur, et n représente 0, 1 ou 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63/205445 | 1988-08-18 | ||
JP20544588 | 1988-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990002119A1 true WO1990002119A1 (fr) | 1990-03-08 |
Family
ID=16506999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1989/000825 WO1990002119A1 (fr) | 1988-08-18 | 1989-08-15 | Derives de 1,2,3,4-tetrahydro-isoquinoline |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1990002119A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0501693A1 (fr) * | 1991-02-27 | 1992-09-02 | Banyu Pharmaceutical Co., Ltd. | Dérivés d'isoquinoleine |
US5362736A (en) * | 1991-02-27 | 1994-11-08 | Banyu Pharmaceutical Co., Ltd. | Isoquinoline derivatives |
US5446164A (en) * | 1993-02-25 | 1995-08-29 | Banyu Pharmaceutical Co., Ltd. | Process for preparing 6,7-dialkoxy-3,4-dihydroisoquinolin-8-ol |
WO2002051842A1 (fr) * | 2000-12-23 | 2002-07-04 | F. Hoffmann-La Roche Ag | Derives de tetrahydropyridine, leur preparation et leur utilisation en tant qu'inhibiteurs de proliferation cellulaire |
WO2003077874A3 (fr) * | 2002-03-13 | 2004-08-05 | Univ Tennessee Res Foundation | Composes tetrahydroisoquinoleine substitues, procedes de preparation et utilisation de ceux-ci |
JP2007528877A (ja) * | 2004-03-12 | 2007-10-18 | アナリットコン エス アー | Igf−1r阻害剤としてのテトラヒドロイソキノリンおよびテトラヒドロベンゾアゼピン誘導体 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4491665A (en) * | 1979-10-19 | 1985-01-01 | Burroughs Wellcome Co. | Method of preparing isomers of bis isoquinolinium compounds |
-
1989
- 1989-08-15 WO PCT/JP1989/000825 patent/WO1990002119A1/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4491665A (en) * | 1979-10-19 | 1985-01-01 | Burroughs Wellcome Co. | Method of preparing isomers of bis isoquinolinium compounds |
Non-Patent Citations (6)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 103, No. 9, see Abstract No. 71575X; & US,A,4491665 (Burroughs Wellcome Co.), 1 January 1985 (01.01.85). * |
CHEMICAL ABSTRACTS, Vol. 61, No. 2, see Abstract Nos. 1829e, 1830c, YAKUGAKU ZASSHI, Vol. 84, No. 4, 329-33 (1964). * |
CHEMICAL ABSTRACTS, Vol. 65, No. 5, see Abstract Nos. 7230b, 7230c; & JP,B,41 007 591 (Dainippon Pharmaceutical Co. Ltd.), 23 April 1966 (23.04.66). * |
CHEMICAL ABSTRACTS, Vol. 74, No. 1, see Abstract No. 3491Z, YAKUGAKU ZASSHI, Vol. 90, No. 9, 1144-9 (1970). * |
CHEMICAL ABSTRACTS, Vol. 81, No. 16, see Abstract No. 98555e, TETRAHEDRON, Vol. 30, No. 8, 931-4 (1974). * |
CHEMICAL ABSTRACTS, Vol. 88, No. 17, see Abstract No. 121486p, HETEROCYCLES, Vol. 9, No. 1, 1-6 (1978). * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0501693A1 (fr) * | 1991-02-27 | 1992-09-02 | Banyu Pharmaceutical Co., Ltd. | Dérivés d'isoquinoleine |
US5362736A (en) * | 1991-02-27 | 1994-11-08 | Banyu Pharmaceutical Co., Ltd. | Isoquinoline derivatives |
US5446164A (en) * | 1993-02-25 | 1995-08-29 | Banyu Pharmaceutical Co., Ltd. | Process for preparing 6,7-dialkoxy-3,4-dihydroisoquinolin-8-ol |
US5498717A (en) * | 1993-02-25 | 1996-03-12 | Banyu Pharmaceutical Co., Ltd. | 6,7-dialkoxy-3,4-diydroisoquinolin-8-yl compounds |
WO2002051842A1 (fr) * | 2000-12-23 | 2002-07-04 | F. Hoffmann-La Roche Ag | Derives de tetrahydropyridine, leur preparation et leur utilisation en tant qu'inhibiteurs de proliferation cellulaire |
US6800638B2 (en) | 2000-12-23 | 2004-10-05 | Hoffman-La Roche Inc. | Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors |
RU2276140C2 (ru) * | 2000-12-23 | 2006-05-10 | Ф.Хоффманн-Ля Рош Аг | Производные тетрагидропиридина и фармацевтическая композиция на их основе |
WO2003077874A3 (fr) * | 2002-03-13 | 2004-08-05 | Univ Tennessee Res Foundation | Composes tetrahydroisoquinoleine substitues, procedes de preparation et utilisation de ceux-ci |
JP2005526770A (ja) * | 2002-03-13 | 2005-09-08 | ザ ユニバーシティ オブ テネシー リサーチ ファウンデイション | 置換テトラヒドロイソキノリン化合物、調製方法、およびその使用 |
US7241774B2 (en) | 2002-03-13 | 2007-07-10 | University Of Tennessee Research Foundation | Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
AU2003230665B2 (en) * | 2002-03-13 | 2010-02-18 | University Of Tennessee Research Foundation | Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
JP2007528877A (ja) * | 2004-03-12 | 2007-10-18 | アナリットコン エス アー | Igf−1r阻害剤としてのテトラヒドロイソキノリンおよびテトラヒドロベンゾアゼピン誘導体 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI62829B (fi) | Foerfarande foer framstaellning av fenoletrar anvaendbara saosom laekemedel | |
US7410964B2 (en) | Cyclohexyl sulphones as gamma-secretase inhibitors | |
CN111032034B (zh) | 螺环化合物及其制造和使用方法 | |
EP3891157A1 (fr) | Composés d'aryle sulfonamide substitués par 4-amino ou 4-alcoxy ayant une activité sélective dans des canaux sodiques sensibles à la tension | |
EA026668B1 (ru) | Новые бициклические пиридиноны | |
JP6174627B2 (ja) | (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の製造方法 | |
US4977146A (en) | 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists | |
KR101494055B1 (ko) | 4,5,6,7-테트라클로로-3'',6''-다이하이드록시-2'',4'',5'',7''- 테트라요오도-3h-스피로[이소벤조푸란-1,9''-잔텐]-3-온(로즈 벤갈) 및 관련 잔텐의 합성 방법 | |
EP1785416A3 (fr) | Analogues de 9, 10-alpha, alpha-OH-Taxane et méthodes pour leur production | |
WO1990002119A1 (fr) | Derives de 1,2,3,4-tetrahydro-isoquinoline | |
US20120189616A1 (en) | Isosorbide nitrates | |
EP0402150A1 (fr) | 2,5-Diaryltétrahydrofurannes et leurs analogues comme antagonistes de PAF | |
JP2022174180A (ja) | 化合物、組成物および方法 | |
DE69126612T2 (de) | Carbamate des indan-pyrrolidins | |
EP1560630A2 (fr) | Derives de 7h-dibenzo[b,g][1,5]dioxocine-5-one et leur utilisation | |
US12084456B2 (en) | Isocarbostyril alkaloids and functionalization thereof | |
US20170217996A1 (en) | Large-scale diastereoselective syntheses of cycloheptadienylsulfones and stereotetrads | |
JP3660395B2 (ja) | フェニルスルホン誘導体及びその製造方法 | |
CA2457451C (fr) | Derives de naphthyridine | |
DE69213049T2 (de) | Isoquinolinderivate | |
EP1894921A3 (fr) | Analogues de 9,10-alpha, alpha-Oh-Taxane et procédés de fabrication correspondants | |
AU2022312844A1 (en) | Hydrogenated quinoxalines | |
Xing et al. | A study of the reaction between 2, 4‐disubstituted‐2, 3‐dihydro‐1, 5‐benzothiazepines and ketenes generated in situ from chloro and dichloroacetyl chlorides | |
WO1996032376A1 (fr) | Nouveaux esters de borneol, leur procede de preparation et leur utilisation pharmaceutique | |
JPS63115858A (ja) | 医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |